L ennoX-Gastaut syndrome (LGS) is an age-specific disorder characterized by the classic triad of epileptic seizures (ie, atonic, tonic, and atypical absence), slow spike-waves in the waking electroencephalogram and fast rhythmic bursts during sleep, and moderate-to-severe cognitive dysfunction.P To date, the optimal therapy for LGS remains uncertain and often includes a combination of various antiepileptic drugs including valproic acid, lamotrigine, topiramate, and felbamate.' Rufinamide is a new oral antiepileptic medication indicated for adjunctive therapy in treating generalized seizures associated with LGS in children aged 4 years and older and adults. Currently, rufinamide is available in tablet formulations of 200 mg and 400 mg.' A liquid dosage form does not exist at the present time. Lack of a suspension formulation may present an administration problem for many children and adults who are unable to swallow tablets. In addition, a weight-based dosage regimen is recommended by the manufacturer upon initiation and titration in the pediatric Author information provided at endof text. BACKGROUND: Rufinamide is an oral antiepileptic drug Indicated for adjunctive therapy in treating generalized seizures associated with Lennox-Gastaut syndrome. Currently, rufinamlde is available as 2QO-mg and 400-mg tablets. A liquid dosage form does not exist at the present time. Lack of a suspension formulation may present an administration problem for manychildren and adults who are unable to swallowtablets. The availability of a liquid dosage form will provide an easyand accurate way to measure and administer the medication. OBJECTIVE: To determine the stability of both sugar-containing and sugar-free rufinamide suspensions over a 9O-day period.
population. The availability of a liquid dosage form will provide an easy and accurate way to measure and administer the medication to a patient.
The purpose of this study was to determine the shortterm stability of an extemporaneously compounded oral liquid dosageform of rufinamide preparedfrom commerciallyavailable tablets.
Methods

SUSPENSION PREPARATION
Twelve 400-mg rufinamide tablets-were thoroughly trituratedin a glass mortar. Sixty mL of Ora-Plus suspension vehicle"was added to the mortar and triturated with the drug powder until a homogeneous suspension was obtained. Sixty mL of Ora-Sweet' or Ora-Sweet SF (sugar free)" flavoring syrup was then added to the suspension and mixed thoroughly to obtain the final suspension (40 mg/mL). A preliminary taste assessment of the 2 suspensions was performedby 2 volunteers. No unpleasant taste was reported,and therefore, no additional formulation adjustmentswerenecessary. Details of the compounding procedureare provided in Appendix I.
STABILITY STUDY
Each of the 2 suspensionsprepared above was divided equally into 3 samples (-40 mL each) and transferred into 60-mL amber polypropylene plastic bottles closed with child-resistant caps" All samples were storedat room temperature(23-25 0c) and assayedafter 0, 7,14,28,56, and 90 days of storage. At each time point, the samples were subjected to visualinspection and reversed-phase high-performance liquid chromatography (RP-HPLC) analysis.In addition,pH measurement was performed' for all samples on day 0 and day 90. Microbiology testing was not included, becauseeach commercial vehiclealready contained effectivepreservatives. The RP-HPLC data were usedto calculate the percentage of the initial drug concentration remaining at each time point. Stability was defined as the retention of at least 90% of the initial concentration.
RP·HPLC METHOD
Each bottlewas shakenthoroughly by hand for approximately 15 seconds immediately before sampling.A 1-mL samplewas withdrawn from each bottleand dilutedto 100 mL in a volumetric flask with sample diluentconsisting of methanol and water (80:20 v/v). The expected rufinamide concentration after dilution was 0.4 mg/mL. The samples were stirredfor I hour and sonicated for 1hour.Due to the viscous nature of the suspension vehicle,it was necessary to disperse the suspension in diluent by stirring prior to sonication. Approximately 3 mL of each samplewas withdrawn and filtered through a 0.45-jlm syringefilters to remove insolubleexcipients. The filtered samples were assayedby RP-HPLC.
RP-HPLC analysis was conducted using a Shimadzu model LC-201OA instrument" equipped with a Cl8 column' maintained at 40°C and UV detector set at 230 nm. The mobile phase consisted of methanol and water (35:65 v/v) with 1 mL/L trifluoroacetic acid delivered at a flow rate of 0.5 mLimin. It was filtered and degassed online before use. For analysis, 10JlL of each samplewas injected by the autosampler. The data were collected and processedby the Shimadzu LCSolution software.The retention timeofrufinamide was 10.9minutes.
Standards of rufinamide at 0.2, 0.3, 0.4, 0.5, and 0.6 mg/mL were prepared in the same samplediluent (methanol:water 80:20 v/v) for the RP-HPLC methodcalibration. Because the pure drug substance of rufinamide was not available commercially, the standards were prepared by using the crushed tablet powder from the commercialtablet dosage form.· The averageweightof the 4OO-mg strength rufinamide tablets was determined to be 740 mg, and calculations were performed to ensurethat the properamount of crushed tablet powder was used to prepare each standard. Once the diluent was added to the crushed tablet powder, the samples were sonicated for 15 minutesfollowedby 2 hours of stirring to ensurefull extraction of the drug substanceinto the diluent.The samples were filtered through 0.45-Jlm Nylon syringe filterss to remove the insoluble tabletexcipients prior to the RP-HPLC analysis. A calibration curve was producedby linear regression of the peak area of rufinarnide against rufinarnide concentration.
The standardcurve was linear (r2 =0.998) over the working range of concentrations. The between-dayand withinday coefficients of variation for the RP-HPLCassay were 0.82% and 0.67%, respectively.
A forceddegradation study of rufinarnide was conducted under extremepH and oxidative stressconditions in order to verify the stability-indicating ability of the RP-HPLC assay. 2. Crush the tablets from step 1 in a glass mortar and triturate to a fine powder.
3. Add 60 mL of Ora-Plus to the rufinamidepowder from step 2 via geometric dilution until a smooth suspension is obtained.
4. Add 60 mL of Ora-Sweet or Ora-Sweet SF (sugar free) to the suspension from step 3 and mix well.
5. Transfer the mixture into a proper amber plastic prescription bailie.
6. Label the bottle "Shake Well Before Use," with an expiration date of 90 days after preparation and store at room temperature. The palatability of the compounded suspensions was also assessed and confirmed to be satisfactory. No additional taste-masking agents are necessary.
It is noteworthy that the 2 strengths of rufinamide tablets share the same excipient composition.' The excipient:drug ratio was also identical in the 2 strengths of tablets, based on the average tablet weight determined in this study (370 mg for the 200-mg strength tablets' and 740 mg for the 400-mg strength tablets"). Therefore, the 200-mg strength tablets can also be used to compound the same suspensions described in this study following the procedures in Appendix I.
Extemporaneously compounded suspensions of rufinamide 40 mg/mL in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 6O-mLamber plastic bottles at room temperature. first prepared by diluting a O.4-mg/mL rufinamide standard solution (see paragraph above) with sample diluent (methanol:water 80:20 v/v). Sample 1 was adjusted to pH 2 using 1 N hydrochloric acid. Sample 2 was adjusted to pH 12 with 1 N sodium hydroxide. Sample 3 and sample 4 were each spiked with 3% hydrogen peroxide (final concentration). Samples 1-3 were incubated at 60 DC for 24 hours. Sample 4 was exposed to direct sunlight for 30 days. RP-HPLC analysis was conducted at the end of each sample treatment. Approximately 4%, 19%,34%, and 95% degradation of rufinamide was observed in samples 1,2,3, and 4, respectively. No interfering peaks from the degradation products were observed. In sample 2, an unidentified degradation product peak was noted at 1.3 relative retention time to rufinamide. No major degradation product peaks were observed for samples 3 and 4, despite the significant amount of loss of parent drug. It was speculated that (I) the oxidation products were polar and coeluted with the solvent front and that (2) the oxidation products did not absorb UV light at 230 run.
Results and Discussion
Rufinamide is commercially available as tablet dosage forms in 2 strengths, 200 mg and 400 mg.' Based on composition listed in the labeling,' the rufinamide tablets are formulated as conventional immediate-release oral tablets containing common excipients and nonfunctional film coating. Therefore, compounding these tablets into powder or suspension dosage forms is not expected to alter the drug's bioavailability or therapeutic effectiveness significantly.
The 40-mg/mL rufinamide suspensions were prepared in this study using 1:1 mixtures of commercially available vehicles (ie, Ora-Plus with either Ora-Sweet or Ora-Sweet SF). Ora-Plus was intended as the main suspending vehicle; Ora-Sweet and Ora-Sweet SF syrups provided flavoring and sweetness for taste masking. All vehicles contained effective preservatives to prevent microbial growth.
The RP-HPLC data of the compounded suspensions are summarized in Table 1 . Both suspensions remained stable (at least 90% of initial concentration) throughout the 90-day study period. In addition, there was no appreciable change in the pH from the initial mean ± SD in any of the samples made with Ora-Sweet (pH 4.43 ±0.08) or in those prepared with Ora-Sweet SF (pH 4.32 ± 0.07) throughout the study period. There was no visible microbial growth in any samples. EXIRAcro TRASFONDO: Rufmarnida es un farmacoantiepileptico oralindicado como terapiaadyuvante en el tratamiento de las crisiscomiciales generalizadas en el sfndrome Lennox-Gastaut. Actualmente, rufmamida se encuentra disponible en la forma de comprimidos de 200 y 400 mg. En estos momentos no hayunaformade presentaei6n liquida. La faltade unaformu-laci6n en suspensi6n puedesuponer un problema de administraci6n en muchosniiiosy adultosque no puedentomarcomprimidos. La disponibilidadde una forma de presentaci6n lfquida proporcionara una forma facil y exactapara mediry administrar la medicaci6n. oBJETIVOS: Determinarla estabilidad de las suspensiones de rufinarnida con y sin aziicarduranteun perfodode 90 dfas. MF:rOVOS: Se prepar6una suspensi6n de rufinarnida de 40 mglmL mediante la pulverizaci6n de 12comprimidos de400 mgde rufmarnida en un morterode cristal.Se mezclaron 60ml de Ora-Plus y 60 mL de Ora-Sweet0 de Ora-SweetSF y se afiadieron aIpolvoparaobtenerun volumenfinalde 120 mL.Se prepararon 3 muestras identicas de cada formulaci6n y se colocaronen dos frascos de plastico de colorambarlno de 60 ml., Se retir6una muestrade 1 mL de cada unode los 6 frascos con una micropipeta inmediatamente despues de la preparaci6n y a los 7, 14,28,56, y 90 dfas.Tras la diluci6n posteriorparauna concentraci6n previstade 0.4 m~mL, las mues~~e ensayaron m~?i ante una . cromatograffa lfquida de alto rendmuento. Las estabilidad se defim6 como la retenci6n de aImenosun 90% de la concentraci6n inicial. RESULTADOS: Al menosel 90% de la concentraci6n inicialde rufinamida permaneci6 durante el perfodo de estudio de 90 dfasen ambospreparados.
StabilityofExtemporaneouslyPreparedRufinamide Oral Suspensions
No se produjeron cambiosdetectables en el color,olor,sabor,y pH ni crecimiento microbiano visible. CONCLUSJONES: Las suspensiones de preparaci6n extemporanea de rufinamida 40 mg/ml en una proporci6n I: I con Ora-Plus y Ora-Sweet o Ora-Sweet SF fueron establesduranteaImenos90 dias cuandose conservaron en frascos de plastico de polipropileno de color ambarino de 60 ml a temperatura ambiente. REsULTATS: Dans les 2 preparations, une valeurminimale de 90% de la concentration initiale de rufinarnide fur observeependantla periodede l'etude de 90 jours. Aucunchangement de couleur, d'odeur, de goutet de PH ne fut detecteet aucunecroissance microbienne ne futvisible. CONCLUSIONS: Les suspensions de rufinarnide 40 mgtmLpreparees extemporanement selonun melange 1/1 (Ora-Plus et Ora-Sweet SF-sanssucre) ont ete stablespendantau moins90 jours, lorsqueconservees a temperatureambiante dansdesbouteilles plastiques en polypropylene d'un volume de 60 mL.
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